Latest Period
Q1 2026
Security Snapshot
AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL) Institutional Ownership
CUSIP: 00288U106
13F Institutional Holders and Ownership History from Q4 2020 to Q1 2026
Institutions Reporting
137
Shares (Excl. Options)
124,252,829
Price
$3.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Shares, no par value per share
- Symbol
- ABCL on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 124,252,829
- Total 13F value
- $433,839,784
- Portfolio coverage rank
- 0%
- Share change
- +15,612,188
- Value change
- +$55,053,547
- Number of holders
- 137
- Shares outstanding
- 305,667,944
- SEC-reported price per share
- $4.77
- Insider filing price
- $4.77
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ABCL - AbCellera Biologics Inc. - Common Shares, no par value per share is tracked under CUSIP 00288U106.
- 137 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 145 to 137 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $370,606,742 to $433,839,784.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 137 institutions filings for Q1 2026.
Security key
00288U106
Latest holder period
Q1 2026
13F holders
137
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
ABCL full holder history
AbCellera Biologics Inc. SEC filings
AbCellera Biologics Inc. company facts
AbCellera Biologics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00288U106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
ABCL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 11% | $120,824,425 | 33,012,138 | Baker Bros. Advisors LP | 30 Apr 2026 | |||
| BAILLIE GIFFORD & CO | 4.4% | $32,881,493 | 12,894,703 | BAILLIE GIFFORD & CO | 30 Sep 2024 |
As of 31 Mar 2026, 137 institutional investors reported holding 124,252,829 shares of AbCellera Biologics Inc. - Common Shares, no par value per share (ABCL). This represents 41% of the company’s total 305,667,944 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
38%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 9.9% | 30,275,938 | +10% | 0.61% | $105,663,024 |
| Capital World Investors | 4.4% | 13,361,096 | 0% | 0.01% | $46,630,225 |
| TWO SIGMA INVESTMENTS, LP | 3.5% | 10,562,065 | +82% | 0.03% | $36,861,607 |
| TD Waterhouse Canada Inc. | 3.1% | 9,564,659 | +42577% | 0.1% | $33,569,696 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.5% | 7,575,476 | -3.8% | 0.01% | $26,438,411 |
| UBS Group AG | 1.4% | 4,209,052 | +117% | 0% | $14,689,591 |
| ArrowMark Colorado Holdings LLC | 1.3% | 4,105,095 | 0% | 0.38% | $14,326,782 |
| BlackRock, Inc. | 1.3% | 4,040,236 | +4.5% | 0% | $14,100,423 |
| Driehaus Capital Management LLC | 1.3% | 4,024,779 | +6.7% | 0.1% | $14,046,479 |
| GOLDMAN SACHS GROUP INC | 1.2% | 3,751,212 | -14% | 0% | $13,091,730 |
| BANK OF AMERICA CORP /DE/ | 0.98% | 2,999,936 | +14% | 0% | $10,469,776 |
| Jefferies Financial Group Inc. | 0.9% | 2,746,200 | 0.12% | $9,584,238 | |
| Alyeska Investment Group, L.P. | 0.85% | 2,592,105 | 0.03% | $9,046,446 | |
| TUDOR INVESTMENT CORP ET AL | 0.74% | 2,273,489 | +27% | 0.04% | $7,934,477 |
| MORGAN STANLEY | 0.73% | 2,224,829 | -26% | 0% | $7,764,653 |
| Guardian Partners Inc. | 0.58% | 1,786,415 | +0% | 0.52% | $6,253,184 |
| RENAISSANCE TECHNOLOGIES LLC | 0.49% | 1,510,629 | -37% | 0.01% | $5,272,095 |
| CITADEL ADVISORS LLC | 0.45% | 1,361,105 | -26% | 0% | $4,750,256 |
| MILLENNIUM MANAGEMENT LLC | 0.42% | 1,294,574 | -27% | 0% | $4,518,063 |
| HRT FINANCIAL LP | 0.4% | 1,235,153 | +125% | 0.01% | $4,310,000 |
| Point72 Asset Management, L.P. | 0.38% | 1,149,325 | +18% | 0.01% | $4,011,144 |
| JANE STREET GROUP, LLC | 0.28% | 847,883 | -39% | 0% | $2,959,112 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.25% | 750,393 | -51% | 0% | $2,618,872 |
| STATE STREET CORP | 0.24% | 730,213 | +5.2% | 0% | $2,548,443 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 0.2% | 610,423 | -12% | 0.01% | $2,130,376 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
22
Latest
Q1 2026
Rows shown
1-22 of 22
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 124,252,829 | $433,839,784 | +$55,053,547 | $3.49 | 137 |
| 2025 Q4 | 108,415,371 | $370,606,742 | -$10,167,392 | $3.42 | 145 |
| 2025 Q3 | 104,032,627 | $524,646,193 | +$3,617,959 | $5.03 | 140 |
| 2025 Q2 | 107,623,463 | $370,594,083 | -$42,109,114 | $3.43 | 127 |
| 2025 Q1 | 124,693,841 | $278,605,461 | +$21,793,003 | $2.23 | 127 |
| 2024 Q4 | 113,909,183 | $333,909,974 | +$23,930,958 | $2.93 | 145 |
| 2024 Q3 | 105,626,999 | $274,569,746 | -$27,524,912 | $2.60 | 139 |
| 2024 Q2 | 114,251,365 | $337,827,363 | -$12,985,717 | $2.96 | 146 |
| 2024 Q1 | 120,885,782 | $546,343,961 | +$6,435,245 | $4.53 | 153 |
| 2023 Q4 | 119,177,804 | $681,087,686 | -$3,743,767 | $5.71 | 141 |
| 2023 Q3 | 120,025,395 | $551,791,208 | -$29,473,838 | $4.60 | 137 |
| 2023 Q2 | 124,831,655 | $809,068,808 | -$42,715,484 | $6.46 | 167 |
| 2023 Q1 | 130,072,488 | $980,706,858 | +$9,956,814 | $7.54 | 181 |
| 2022 Q4 | 138,959,875 | $1,408,301,843 | +$64,970,441 | $10.13 | 198 |
| 2022 Q3 | 132,080,272 | $1,309,587,378 | +$125,586,082 | $9.89 | 185 |
| 2022 Q2 | 117,984,795 | $1,259,732,308 | +$77,596,210 | $10.65 | 160 |
| 2022 Q1 | 113,127,329 | $1,100,172,856 | -$30,931,776 | $9.75 | 126 |
| 2021 Q4 | 114,533,051 | $1,628,519,417 | +$98,165,187 | $14.30 | 120 |
| 2021 Q3 | 98,697,276 | $1,977,505,786 | +$155,909,310 | $20.04 | 115 |
| 2021 Q2 | 90,556,840 | $1,986,081,198 | +$169,321,459 | $22.00 | 111 |
| 2021 Q1 | 71,121,706 | $2,415,006,720 | +$64,105,935 | $33.96 | 82 |
| 2020 Q4 | 68,103,635 | $2,740,470,000 | +$2,587,818,000 | $40.24 | 58 |